Futura Medical Regulatory News (FUM)

Futura Medical plc

("Futura" or "the Company")

Remuneration of Non-Executive Directors

Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, announces the issue of 40,392 new ordinary shares in respect of the 2014 remuneration of its Non-Executive Directors.

In accordance with the announcement of 13 January 2014, Non-Executive Directors receive approximately 30 per cent of their remuneration in the Company's ordinary shares. For 2014 these were issued at 63.25 pence per share, being the average closing mid-price of the last 10 trading days of 2013. The 40,392 new ordinary shares shall rank pari passu with the existing issued ordinary shares of the Company and have been issued as follows:

Application has been made to the London Stock Exchange and it is anticipated that trading of the new ordinary shares will commence on AIM at 8:00am on 9 January 2015.

Immediately following the above issue, the Company will have 99,022,600 Ordinary Shares in issue. Since the Company currently holds no shares in treasury, the total number of voting rights in the Company is therefore 99,022,600 and this figure may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

The shares element of the Non-Executive Directors' remuneration for 2015 will be awarded at 35.50 pence per share, being the average closing mid-price of the last 10 trading days of 2014. The Non-Executive Directors will receive the shares at the end of the 2015 financial year.

Full details of Non-Executive Directors' remuneration will be included in the Company's Annual Report & Accounts.

For further information please contact:

Notes to editors:

About Futura Medical plc

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.

www.futuramedical.com